thiosulfates has been researched along with Calcinosis in 52 studies
Thiosulfates: Inorganic salts of thiosulfuric acid possessing the general formula R2S2O3.
thiosulfate(2-) : A divalent inorganic anion obtained by removal of both protons from thiosulfuric acid.
Calcinosis: Pathologic deposition of calcium salts in tissues.
Excerpt | Relevance | Reference |
---|---|---|
"In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017." | 7.91 | Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017. ( Davis, MDP; Ernste, FC; Ma, JE; Wetter, DA, 2019) |
"We report the successful use of abatacept and sodium thiosulfate in a patient with severe recalcitrant juvenile dermatomyositis complicated by ulcerative skin disease and progressive calcinosis." | 7.78 | Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. ( Arabshahi, B; Jones, OY; Rider, LG; Silverman, RA, 2012) |
"We report a patient with diffuse systemic sclerosis who presented with two symmetrical plaques on both axillae, which caused pain and skin retraction." | 6.72 | Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review. ( Corrales-Martínez, AF; Durán-Vian, C; Gómez-Fernández, C; González-López, MA; López-Sundh, AE; Quintana-Sancho, A; Reguero-DelCura, L, 2021) |
"Calciphylaxis is associated with medial arteriolar vascular calcification and results in ischemic subcutaneous necrosis with vulnerable skin ulcerations and high mortality." | 6.43 | Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. ( Hayden, MR; Khanna, R; Kolb, L; Sowers, JR; Tyagi, SC, 2005) |
"Treatment with sodium thiosulfate provides good results; however, intralesional and intravenous treatment can be limited by its adverse effects." | 5.72 | Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis. ( Gómez, C; Morales, P; Requena, S; Santos-Juanes, J, 2022) |
"Pseudopseudohypoparathyroidism is an imprinted GNAS spectrum disorder that induces the phenotype of Albright's hereditary osteodystrophy." | 5.72 | Intralesional sodium thiosulfate treatment of calcinosis cutis in pseudopseudohypoparathyroidism. ( Brokamp, G; Mosser-Goldfarb, J, 2022) |
"Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive disorder." | 5.72 | The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in ( Döneray, H; Gürbüz, K; Özden, A, 2022) |
"Familial hyperphosphatemic tumoral calcinosis is a rare disorder characterized by hyperphosphatemia with recurrent ectopic periarticular calcifications, in addition to other visceral and vascular manifestations, without any inflammatory or neoplastic disorder." | 5.62 | Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate. ( Aktasoglu, E; Emecen Sanli, M; Ezgu, F; Inci, A; Kilic, A; Okur, I; Tumer, L, 2021) |
" Numerous side-effects prompted dosage adjustment to 10 g intravenously daily." | 5.56 | Severe early-onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate. ( Bourrat, E; Kauffenstein, G; Leftheriotis, G; Martin, L; Navasiolava, N; Nitschke, Y; Omarjee, L; Rutsch, F; Vanakker, OM; Verschuere, S; Vignon, MD, 2020) |
"The calcinosis was recalcitrant to treatment with topical steroids and hydroxychloroquine." | 5.51 | Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate. ( Frigerio, A; Haynes, D; Hull, C; Topham, C, 2019) |
"Available treatments for calcinosis cutis are unsatisfactory, but given the recent use of topical and intralesional sodium thiosulfate (STS) to treat calcifying disorders, we sought to describe the use of intravenous (IV) STS for CTD-associated dystrophic calcinosis cutis." | 5.48 | Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. ( Costner, M; Fett, NM; Lin, J; Merola, JF; Song, P; Vleugels, RA, 2018) |
"However, its effect on tumoral calcinosis (TC) complicating autoimmune connective-tissue diseases has been scarcely described." | 5.46 | Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases. ( Bardin, T; Ea, HK; Guigonis, V; Mageau, A; Ratzimbasafy, V; Richette, P; Urena, P, 2017) |
"Hyperphosphatemic familial tumoral calcinosis (HFTC) and hyperphosphatemia hyperostosis syndrome (HHS) are rare diseases characterized by hyperphosphatemia and ectopic calcifications or recurrent episodes of diaphysitis." | 5.43 | Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis? ( Bahans, C; Benistan, K; Courbebaisse, M; Guigonis, V; Jost, J; Lienhardt, A; Linglart, A; Mutar, H; Pfender, E; Ratsimbazafy, V; Tran, TA, 2016) |
" Sodium thiosulfate (STS) has recently been used with success in the treatment of tumoral calcinosis." | 5.34 | Tolerance and effect of sodium thiosulfate in calcific tendinitis of the rotator cuff. ( Bertrand-Vasseur, A; Darrieurtort-Laffite, C; Garraud, T; Le Goff, B; Planche, L, 2020) |
"In this case series, we retrospectively identified all patients treated with topical sodium thiosulfate (TST) for calcinosis cutis (CC) associated with underlying autoimmune connective tissue diseases at Mayo Clinic (Rochester, MN, USA) during the period 1 January 2012 to 27 June 2017." | 3.91 | Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017. ( Davis, MDP; Ernste, FC; Ma, JE; Wetter, DA, 2019) |
"We report the successful use of abatacept and sodium thiosulfate in a patient with severe recalcitrant juvenile dermatomyositis complicated by ulcerative skin disease and progressive calcinosis." | 3.78 | Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. ( Arabshahi, B; Jones, OY; Rider, LG; Silverman, RA, 2012) |
"We recommend topical sodium thiosulfate 25% as an alternative treatment for dystrophic calcinosis cutis." | 3.77 | A novel treatment for ulcerative calcinosis cutis. ( Bair, B; Fivenson, D, 2011) |
"We report a patient with diffuse systemic sclerosis who presented with two symmetrical plaques on both axillae, which caused pain and skin retraction." | 2.72 | Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review. ( Corrales-Martínez, AF; Durán-Vian, C; Gómez-Fernández, C; González-López, MA; López-Sundh, AE; Quintana-Sancho, A; Reguero-DelCura, L, 2021) |
"We have limited data on the treatment of calcinosis cutis associated with systemic sclerosis and dermatomyositis." | 2.66 | Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. ( Aggarwal, R; Arnaud, L; Barbaud, A; Chasset, F; Chizzolini, C; Francès, C; Monfort, JB; Oddis, CV; Senet, P; Traineau, H, 2020) |
"Calciphylaxis is defined as calcification of the media of small- and medium-sized blood vessels in the dermis and subcutaneous tissue." | 2.52 | Calcinosis Cutis and Calciphylaxis. ( Jiménez-Gallo, D; Linares-Barrios, M; Ossorio-García, L, 2015) |
"Calciphylaxis is associated with medial arteriolar vascular calcification and results in ischemic subcutaneous necrosis with vulnerable skin ulcerations and high mortality." | 2.43 | Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. ( Hayden, MR; Khanna, R; Kolb, L; Sowers, JR; Tyagi, SC, 2005) |
"Pseudopseudohypoparathyroidism is an imprinted GNAS spectrum disorder that induces the phenotype of Albright's hereditary osteodystrophy." | 1.72 | Intralesional sodium thiosulfate treatment of calcinosis cutis in pseudopseudohypoparathyroidism. ( Brokamp, G; Mosser-Goldfarb, J, 2022) |
"Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive disorder." | 1.72 | The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in ( Döneray, H; Gürbüz, K; Özden, A, 2022) |
"Treatment with sodium thiosulfate provides good results; however, intralesional and intravenous treatment can be limited by its adverse effects." | 1.72 | Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis. ( Gómez, C; Morales, P; Requena, S; Santos-Juanes, J, 2022) |
"Familial hyperphosphatemic tumoral calcinosis is a rare disorder characterized by hyperphosphatemia with recurrent ectopic periarticular calcifications, in addition to other visceral and vascular manifestations, without any inflammatory or neoplastic disorder." | 1.62 | Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate. ( Aktasoglu, E; Emecen Sanli, M; Ezgu, F; Inci, A; Kilic, A; Okur, I; Tumer, L, 2021) |
" Numerous side-effects prompted dosage adjustment to 10 g intravenously daily." | 1.56 | Severe early-onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate. ( Bourrat, E; Kauffenstein, G; Leftheriotis, G; Martin, L; Navasiolava, N; Nitschke, Y; Omarjee, L; Rutsch, F; Vanakker, OM; Verschuere, S; Vignon, MD, 2020) |
"The calcinosis was recalcitrant to treatment with topical steroids and hydroxychloroquine." | 1.51 | Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate. ( Frigerio, A; Haynes, D; Hull, C; Topham, C, 2019) |
"Available treatments for calcinosis cutis are unsatisfactory, but given the recent use of topical and intralesional sodium thiosulfate (STS) to treat calcifying disorders, we sought to describe the use of intravenous (IV) STS for CTD-associated dystrophic calcinosis cutis." | 1.48 | Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. ( Costner, M; Fett, NM; Lin, J; Merola, JF; Song, P; Vleugels, RA, 2018) |
"Calcium gluconate extravasation is a process that can cause serious lesions, such as necrosis and calcification of the soft tissues." | 1.48 | The Use of Antidotes for Calcium Gluconate Extravasation: An Experimental Study in Mice. ( Centeno Cortés, A; de Toro Santos, FJ; López San Martín, P; Midón Míguez, J; Mosquera Osés, JJ; Pacheco Compaña, FJ; Yebra-Pimentel Vidal, MT, 2018) |
"However, its effect on tumoral calcinosis (TC) complicating autoimmune connective-tissue diseases has been scarcely described." | 1.46 | Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases. ( Bardin, T; Ea, HK; Guigonis, V; Mageau, A; Ratzimbasafy, V; Richette, P; Urena, P, 2017) |
"Hyperphosphatemic familial tumoral calcinosis (HFTC) and hyperphosphatemia hyperostosis syndrome (HHS) are rare diseases characterized by hyperphosphatemia and ectopic calcifications or recurrent episodes of diaphysitis." | 1.43 | Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis? ( Bahans, C; Benistan, K; Courbebaisse, M; Guigonis, V; Jost, J; Lienhardt, A; Linglart, A; Mutar, H; Pfender, E; Ratsimbazafy, V; Tran, TA, 2016) |
"ESRD was secondary to nephronophthisis (n = 1), membranoproliferative glomerulonephritis (n = 1), diabetic nephropathy (n = 1), and thrombotic microangiopathy (n = 1)." | 1.40 | Sodium thiosulphate treatment of uraemic tumoral calcinosis. ( Bardin, T; Cohen-Solal, M; Ea, HK; Lioté, F; Malbos, S; Trout, H; Urena-Torres, P, 2014) |
"Treatment with sodium thiosulfate (STS) and hyperbaric oxygen (HBO) therapy alone was ineffective, forcing the patient to undergo bilateral below the-knee-amputation (BKA) 5 months after presentation." | 1.36 | Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient. ( Amin, N; Gonzalez, E; Lieber, M; Salusky, IB; Zaritsky, JJ, 2010) |
"Treatment with sodium thiosulfate resulted in dramatic scintigraphic improvement." | 1.35 | Bone scan findings in metastatic calcification from calciphylaxis. ( Leslie, WD; Soni, S, 2008) |
"Sodium thiosulfate treatment transiently lowered plasma ionized calcium and induced metabolic acidosis." | 1.35 | Sodium thiosulfate prevents vascular calcifications in uremic rats. ( Farese, S; Frey, BM; Frey, FJ; Huynh-Do, U; Pasch, A; Schaffner, T, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (3.85) | 18.2507 |
2000's | 6 (11.54) | 29.6817 |
2010's | 27 (51.92) | 24.3611 |
2020's | 17 (32.69) | 2.80 |
Authors | Studies |
---|---|
Ricardo, JW | 1 |
Sun, HY | 1 |
Gorji, M | 1 |
Sebaratnam, DF | 1 |
Requena, S | 1 |
Santos-Juanes, J | 1 |
Morales, P | 1 |
Gómez, C | 1 |
Brokamp, G | 1 |
Mosser-Goldfarb, J | 1 |
Le, Q | 1 |
Robinson, A | 1 |
Stevens, W | 1 |
Li, J | 2 |
Tubau, C | 1 |
Cubiró, X | 1 |
Amat-Samaranch, V | 1 |
Garcia-Melendo, C | 1 |
Puig, L | 1 |
Roé-Crespo, E | 1 |
Bhari, N | 1 |
Bharti, P | 1 |
Omarjee, L | 1 |
Nitschke, Y | 1 |
Verschuere, S | 1 |
Bourrat, E | 1 |
Vignon, MD | 1 |
Navasiolava, N | 1 |
Leftheriotis, G | 1 |
Kauffenstein, G | 1 |
Rutsch, F | 1 |
Vanakker, OM | 1 |
Martin, L | 1 |
Darrieurtort-Laffite, C | 1 |
Bertrand-Vasseur, A | 1 |
Garraud, T | 1 |
Planche, L | 1 |
Le Goff, B | 1 |
Boyce, AM | 1 |
Gafni, RI | 1 |
Ferreira, CR | 1 |
Yan, M | 1 |
Ren, L | 1 |
Deng, H | 1 |
Wen, R | 1 |
Howard, RM | 1 |
Smith, GP | 2 |
von Hodenberg, C | 1 |
Neufeld, M | 1 |
Wohlrab, J | 1 |
Meyer, D | 1 |
Ehrchen, J | 1 |
Sunderkötter, C | 1 |
Badawi, AH | 1 |
Patel, V | 1 |
Warner, AE | 1 |
Hall, JC | 1 |
López-Sundh, AE | 1 |
Quintana-Sancho, A | 1 |
Durán-Vian, C | 1 |
Reguero-DelCura, L | 1 |
Corrales-Martínez, AF | 1 |
Gómez-Fernández, C | 1 |
González-López, MA | 1 |
Döneray, H | 1 |
Özden, A | 1 |
Gürbüz, K | 1 |
Emecen Sanli, M | 1 |
Kilic, A | 1 |
Aktasoglu, E | 1 |
Inci, A | 1 |
Okur, I | 1 |
Ezgu, F | 1 |
Tumer, L | 1 |
Müller, C | 1 |
Tanew, A | 1 |
Laml-Wallner, G | 1 |
Radakovic, S | 1 |
García-García, E | 1 |
López-López, R | 1 |
Álvarez-Del-Vayo, C | 1 |
Bernabeu-Wittel, J | 1 |
Gunasekera, NS | 1 |
Maniar, LEG | 1 |
Lezcano, C | 1 |
Laga, AC | 1 |
Merola, JF | 2 |
Song, P | 1 |
Fett, NM | 1 |
Lin, J | 1 |
Costner, M | 1 |
Vleugels, RA | 1 |
Goossens, J | 1 |
Courbebaisse, M | 2 |
Caudron, E | 1 |
Bahans, C | 3 |
Vacquerie, V | 1 |
Melchior, J | 1 |
Salle, PV | 1 |
Moesch, C | 1 |
Daudon, M | 1 |
Frocht, V | 1 |
Richette, P | 2 |
Ea, HK | 3 |
Guigonis, V | 4 |
Fiel, DC | 1 |
Margarido Malvar, HB | 1 |
Dias Silva, RA | 1 |
Rosenbach, M | 1 |
Pacheco Compaña, FJ | 1 |
Midón Míguez, J | 1 |
de Toro Santos, FJ | 1 |
Centeno Cortés, A | 1 |
López San Martín, P | 1 |
Yebra-Pimentel Vidal, MT | 1 |
Mosquera Osés, JJ | 1 |
Ma, JE | 1 |
Ernste, FC | 1 |
Davis, MDP | 1 |
Wetter, DA | 1 |
Topham, C | 1 |
Haynes, D | 1 |
Frigerio, A | 1 |
Hull, C | 1 |
Rodelo-Haad, C | 1 |
Esquivias-Motta, E | 1 |
Amaral-Neiva, F | 1 |
Martin-Malo, A | 1 |
Aljama, P | 1 |
Rodriguez, M | 1 |
Taillé, C | 1 |
Debray, MP | 1 |
Danel, C | 1 |
Serhal, A | 1 |
Pradère, P | 1 |
Crestani, B | 1 |
Traineau, H | 1 |
Aggarwal, R | 1 |
Monfort, JB | 1 |
Senet, P | 1 |
Oddis, CV | 1 |
Chizzolini, C | 1 |
Barbaud, A | 1 |
Francès, C | 1 |
Arnaud, L | 1 |
Chasset, F | 1 |
Christie, M | 1 |
Roscoe, J | 1 |
Chee, J | 1 |
Inparajah, M | 1 |
Vaughn-Neil, T | 1 |
Nagai, G | 1 |
Ng, P | 1 |
Fung, J | 1 |
Ting, R | 1 |
Tam, P | 1 |
Sikaneta, T | 1 |
Malbos, S | 1 |
Urena-Torres, P | 1 |
Cohen-Solal, M | 1 |
Trout, H | 1 |
Lioté, F | 1 |
Bardin, T | 2 |
Baumgartner-Nielsen, J | 1 |
Olesen, AB | 1 |
Jiménez-Gallo, D | 1 |
Ossorio-García, L | 1 |
Linares-Barrios, M | 1 |
Young, G | 1 |
Putt, T | 1 |
Schollum, J | 1 |
Walker, R | 1 |
Jost, J | 1 |
Tran, TA | 1 |
Linglart, A | 1 |
Benistan, K | 1 |
Lienhardt, A | 1 |
Mutar, H | 1 |
Pfender, E | 1 |
Ratsimbazafy, V | 2 |
Mageau, A | 1 |
Ratzimbasafy, V | 1 |
Urena, P | 1 |
Soni, S | 1 |
Leslie, WD | 1 |
Pasch, A | 1 |
Schaffner, T | 1 |
Huynh-Do, U | 1 |
Frey, BM | 1 |
Frey, FJ | 1 |
Farese, S | 1 |
O'Neill, WC | 2 |
Wolf, EK | 1 |
Smidt, AC | 1 |
Laumann, AE | 1 |
Amin, N | 1 |
Gonzalez, E | 1 |
Lieber, M | 1 |
Salusky, IB | 1 |
Zaritsky, JJ | 1 |
Adirekkiat, S | 1 |
Sumethkul, V | 1 |
Ingsathit, A | 1 |
Domrongkitchaiporn, S | 1 |
Phakdeekitcharoen, B | 1 |
Kantachuvesiri, S | 1 |
Kitiyakara, C | 1 |
Klyprayong, P | 1 |
Disthabanchong, S | 1 |
Park, YH | 1 |
Park, CH | 1 |
Kim, HJ | 1 |
Lomashvili, KA | 1 |
Bair, B | 1 |
Fivenson, D | 1 |
Arabshahi, B | 1 |
Silverman, RA | 1 |
Jones, OY | 1 |
Rider, LG | 1 |
Hayden, MR | 1 |
Tyagi, SC | 1 |
Kolb, L | 1 |
Sowers, JR | 1 |
Khanna, R | 1 |
Tokashiki, K | 1 |
Ishida, A | 1 |
Kouchi, M | 1 |
Ishihara, S | 1 |
Tomiyama, N | 1 |
Kohagura, K | 1 |
Iseki, K | 1 |
Takishita, S | 1 |
Papadakis, JT | 1 |
Patrikarea, A | 1 |
Digenis, GE | 1 |
Stamatelou, K | 1 |
Ntaountaki, I | 1 |
Athanasopoulos, V | 1 |
Tamvakis, N | 1 |
Kyriakopoulos, G | 1 |
Kontogianni, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Placebo-controlled Trial of the Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis.[NCT06155578] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2024-01-02 | Not yet recruiting | ||
Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff[NCT02538939] | Phase 2 | 17 participants (Actual) | Interventional | 2015-12-02 | Completed | ||
A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC)[NCT01918904] | Phase 2 | 0 participants (Actual) | Interventional | 2013-09-30 | Withdrawn (stopped due to PI decided not to proceed with this project. No participants were enrolled.) | ||
A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome[NCT03215927] | Phase 2 | 20 participants (Actual) | Interventional | 2017-06-01 | Active, not recruiting | ||
Abatacept for the Treatment of Refractory Juvenile Dermatomyositis[NCT02594735] | Phase 4 | 10 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Patients who have achieved Definition of Improvement (DOI) at week 6 (visit 2) or at any point thereafter and is rated by their study physician as at least minimally improved, then tapering of corticosteroids may commence using a precise dose reduction schedule as follows:~For patients taking 40 to 60 mg daily, prednisone will be tapered by 10 mg ,For patients taking 20 to 35 mg daily, prednisone will be tapered by 5 mg. For patients taking 7.5 to 15 mg daily, prednisone will be tapered by 2.5 mg. For patients taking 1 to 5 mg daily, prednisone will be tapered by 1 mg For patients receiving intravenous pulse methylprednisolone therapy, they may alternatively reduce the dose of IV therapy, instead of oral by a decrease of 25%" (NCT02594735)
Timeframe: week 0 to week 24
Intervention | mg (Mean) |
---|---|
Week 0 (Baseline) | 16.7 |
Week 24 | 10.2 |
Physical function will be measured by using the Stanford HAQ/CHAQ: Childhood Health Assessment Questionnaire: The Stanford HAQ is a brief self-report questionnaire assessing physical function pertaining to activities of daily living in a variety of domains. The CHAQ was adapted directly from the HAQ and it has also been successfully applied to patients with juvenile myositis, with scores ranging from 0 to 3. Lower scores indicate less physical disability. (NCT02594735)
Timeframe: week 0 to 24
Intervention | units on a scale (Mean) |
---|---|
Week 0 (Baseline) | 1.84 |
Week 24 | 0.88 |
Cutaneous disease activity will be measured using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). CDASI is a clinician-scored instrument that separately measures activity and damage in the skin of dermatomyositis patients for use in clinical practice or clinical/therapeutic studies. Cutaneous disease activity was measured via the activity sub-score of CDASI, ranging from 0-100. Higher scores indicate more disease activity. (NCT02594735)
Timeframe: week 0 to week 24
Intervention | score on a scale (Mean) |
---|---|
Week 0 (Baseline) | 21.4 |
Week 24 | 14.0 |
The extramuscular activity will be measured by using the Myositis Disease Activity Assessment Tool (MDAAT). This validated tool measures the degree of disease activity of extra-muscular organ systems and muscle on a 0 - 10 cm visual analogue scale (VAS). Extramuscular activity ranges between 0 and 10 via VAS. Lower scores indicate lower disease activity. (NCT02594735)
Timeframe: week 0 to 24
Intervention | units on a scale (Mean) |
---|---|
Week 0 (Baseline) | 4.1 |
Week 24 | 2.4 |
Muscle strength will be measured using an abbreviated Manual Muscle Testing (MMT) in 8 muscles (MMT8) ranging between 0 and 10 for each muscle bilaterally (with the exception of neck flexors, for a total of 15 muscles) with a total score ranging between 0 and 150. Higher scores indicate higher muscle strength. (NCT02594735)
Timeframe: week 0 to week 24
Intervention | units on a scale (Mean) |
---|---|
Week 0 (Baseline) | 121.8 |
Week 24 | 137.2 |
"The muscle enzymes include creatine kinase (CK), aldolase, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). If more than one muscle enzyme is identified as being elevated (a minimum level of 1.3 x the upper limit of normal), then the most abnormal will be selected and this enzyme will be the target enzyme followed to evaluate disease improvement or worsening.~In order to standardize the change in muscle enzymes selected as most abnormal across patients, the outcome measurement was calculated as the most abnormal enzyme level measured via bloodwork divided by the upper limit normal of the healthy reference range (i.e percentage of the upper limit normal for the respective muscle enzyme). Higher percentages indicate higher muscle enzyme levels." (NCT02594735)
Timeframe: week 0 to 24
Intervention | percentage of upper limit normal (Mean) |
---|---|
Week 0 (Baseline) | 1.52 |
Week 24 | 1.52 |
This tool measures the global evaluation y the patient, or by the parent if the patient is a minor, of the patient's overall disease activity at the time of assessment using a 10 cm. visual analogue scale (VAS). Parent/Patient Global Activity ranges between 0 and 10 via VAS. Lower scores indicate less disease activity. (NCT02594735)
Timeframe: week 0 to 24
Intervention | units on a scale (Mean) |
---|---|
Week 0 (Baseline) | 5.3 |
Week 24 | 2.3 |
This tool measures the global evaluation by the treating physician of the overall disease activity of the patient at the time of assessment using a 10 cm visual analogue scale (VAS). Physician global activity ranges between 0 and 10 via VAS. Lower scores indicate less disease activity. (NCT02594735)
Timeframe: week 0 to week 24
Intervention | units on a scale (Mean) |
---|---|
Week 0 (Baseline) | 5.0 |
Week 24 | 2.6 |
Axial STIR and T1 MRI images of bilateral thighs and pelvis were obtained at baseline and week 24. Images were coded and reviewed independently by two musculoskeletal radiologists who had comparable inter-observer variability and were blinded to any subject data, including visit number. MRI scoring was performed utilizing a 4-point scale (0-normal, 1-mild, 2-moderate, 3-severe) for muscle edema for each of the muscle groups examined, i.e. gluteal, adductors, hamstrings, and quadriceps, resulting in an aggregate score between 0 to 12. (NCT02594735)
Timeframe: week 0 to week 24
Intervention | score on a scale (Mean) |
---|---|
Week 0 (Baseline) | 5.3 |
Week 24 | 2.3 |
"The ACR-EULAR Response Criteria use a continuous total improvement score from baseline (range 0-100) based on the sum of the absolute percent change in the 6 core domains (weighted) used in the IMACS DOI (International Myositis Assessment and Clinical Studies definition of improvement)~IMACS core measures are: Physician Global Assessment of Disease Activity (PGA), Patient (Subject) Global Assessment of Disease Activity (SGA), Manual Muscle Test (MMT-8), Health Assessment Questionnaire-Disability Index (HAQ-DI), Muscle Enzyme levels, Myositis Disease Activity Assessment Tool (MDAAT) Extramuscular Global Activity.~In children, the total improvement score ranges between 0 and 100 percent corresponds to the degree of improvement, with higher scores corresponding to a greater degree of improvement ( >/= 30 represents minimal improvement, a score of >/= 45 represents moderate improvement, and a score of >/= 75 represents major improvement)." (NCT02594735)
Timeframe: week 0 to week 24
Intervention | score on a scale (Mean) |
---|---|
Open Label (One Arm) | 53.8 |
Safety will be assessed by review of adverse events using NCI Common Terminology criteria v5.0 November 2017. Particular attention to serious adverse events and infections will be given. An adverse event diary will be maintained throughout the study. Patient evaluations will include: vital sign measurement, physical examination, and laboratory parameters for hematology and routine chemistries (NCT02594735)
Timeframe: week 0 to week 24
Intervention | events (Number) | |||||||
---|---|---|---|---|---|---|---|---|
Worsening of interstitial lung disease | Compression fracture | Right knee contracture worsening | Worsening calcinosis | Lipoatrophy, focal | Febrile episodes | Skin-infection | E. coli diarrhea | |
Open Label (One Arm) | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 |
8 reviews available for thiosulfates and Calcinosis
Article | Year |
---|---|
Topical sodium thiosulfate as treatment of calcinosis cutis: Case series and systematic review.
Topics: Calcinosis; Humans; Skin Diseases; Thiosulfates | 2022 |
Generalized Arterial Calcification of Infancy: New Insights, Controversies, and Approach to Management.
Topics: Adenosine Monophosphate; Bone Density Conservation Agents; Calcinosis; Cardiovascular Agents; Chelat | 2020 |
Clinical and ultrasound response to intralesional sodium thiosulfate for the treatment of calcinosis cutis in the setting of systemic sclerosis. A case-based review.
Topics: Calcinosis; Humans; Scleroderma, Systemic; Skin Diseases; Thiosulfates | 2021 |
Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature.
Topics: Calcinosis; Dermatologic Surgical Procedures; Dermatomyositis; Diltiazem; Humans; Injections, Intral | 2020 |
Calcinosis Cutis and Calciphylaxis.
Topics: Autoimmune Diseases; Calcinosis; Calciphylaxis; Calcium; Collagen Diseases; Diagnostic Imaging; Huma | 2015 |
Treatment of vascular calcification.
Topics: Animals; Calcinosis; Humans; Kidney Diseases; Renal Circulation; Thiosulfates; Vascular Diseases | 2008 |
Recent progress in the treatment of vascular calcification.
Topics: Animals; Calcinosis; Diphosphonates; Disease Models, Animal; Humans; Kidney Diseases; Thiosulfates; | 2010 |
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate.
Topics: Animals; Antioxidants; Arteries; Atherosclerosis; Calcinosis; Calciphylaxis; Chelating Agents; Chron | 2005 |
1 trial available for thiosulfates and Calcinosis
Article | Year |
---|---|
Tolerance and effect of sodium thiosulfate in calcific tendinitis of the rotator cuff.
Topics: Adult; Calcinosis; Chelating Agents; Female; Humans; Injections, Intralesional; Male; Middle Aged; P | 2020 |
43 other studies available for thiosulfates and Calcinosis
Article | Year |
---|---|
Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis.
Topics: Aged; Antioxidants; Calcinosis; Calciphylaxis; Humans; Hyperostosis, Cortical, Congenital; Hyperphos | 2022 |
Intralesional sodium thiosulfate treatment of calcinosis cutis in pseudopseudohypoparathyroidism.
Topics: Adolescent; Calcinosis; Humans; Pseudohypoparathyroidism; Pseudopseudohypoparathyroidism; Skin Neopl | 2022 |
Recalcitrant digital calcinosis cutis successfully treated with intralesional sodium thiosulfate under digital nerve blockade.
Topics: Calcinosis; Humans; Nerve Block; Quality of Life; Skin Diseases; Thiosulfates | 2022 |
Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate.
Topics: Calcinosis; Follow-Up Studies; Humans; Thiosulfates; Ultrasonography | 2022 |
Dystrophic calcinosis cutis in autosomal recessive dystrophic epidermolysis bullosa.
Topics: Administration, Topical; Calcinosis; Child; Epidermolysis Bullosa Dystrophica; Female; Genetic Couns | 2019 |
Severe early-onset manifestations of pseudoxanthoma elasticum resulting from the cumulative effects of several deleterious mutations in ENPP1, ABCC6 and HBB: transient improvement in ectopic calcification with sodium thiosulfate.
Topics: Calcinosis; Humans; Male; Multidrug Resistance-Associated Proteins; Mutation; Phenotype; Phosphoric | 2020 |
Intravenous sodium thiosulfate combined with parathyroidectomy as a cure for uremic tumoral calcinosis in a hemodialysis patient.
Topics: Calcinosis; Humans; Kidney Failure, Chronic; Parathyroidectomy; Renal Dialysis; Thiosulfates | 2021 |
Treatment of calcinosis cutis with sodium thiosulfate therapy.
Topics: Antioxidants; Calcinosis; Humans; Retrospective Studies; Skin Diseases; Thiosulfates | 2020 |
Topical sodium thiosulfate: a reliable treatment for digital calcinosis cutis - a case series with six patients.
Topics: Calcinosis; Humans; Skin Diseases; Skin Neoplasms; Thiosulfates | 2020 |
Dystrophic calcinosis cutis: treatment with intravenous sodium thiosulfate.
Topics: Administration, Intravenous; Calcinosis; Female; Humans; Middle Aged; Skin Diseases; Thiosulfates; T | 2020 |
The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in
Topics: Acetazolamide; Calcinosis; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperosto | 2022 |
Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate.
Topics: Acetazolamide; Administration, Topical; Anticonvulsants; Antioxidants; Calcinosis; Chelating Agents; | 2021 |
Successful treatment of calcinosis cutis with a topical sodium thiosulphate preparation containing 20% zinc oxide in a patient with sclerotic graft-versus-host disease.
Topics: Calcinosis; Graft vs Host Disease; Humans; Skin Diseases; Thiosulfates; Zinc Oxide | 2022 |
Iatrogenic Calcinosis Cutis Successfully Treated with Topical Sodium Thiosulfate.
Topics: Administration, Topical; Calcinosis; Child; Humans; Iatrogenic Disease; Male; Skin Diseases; Thiosul | 2017 |
Intralesional Sodium Thiosulfate Treatment for Calcinosis Cutis in the Setting of Lupus Panniculitis.
Topics: Adult; Antioxidants; Calcinosis; Female; Humans; Injections, Intralesional; Panniculitis, Lupus Eryt | 2017 |
Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis.
Topics: Antioxidants; Calcinosis; Chelating Agents; Connective Tissue Diseases; Dermatologic Agents; Female; | 2018 |
Efficacy of intralesional sodium thiosulfate injections for disabling tumoral calcinosis: Two cases.
Topics: Adult; Calcinosis; Chelating Agents; Dermatomyositis; Female; Fibroblast Growth Factor-23; Humans; H | 2017 |
The role of mammography in calcific uremic arteriolopathy.
Topics: Aged; Arterioles; Biopsy; Calcinosis; Debridement; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2017 |
Calcinosis cutis: a rock and a hard place.
Topics: Calcinosis; Connective Tissue Diseases; Humans; Thiosulfates | 2018 |
The Use of Antidotes for Calcium Gluconate Extravasation: An Experimental Study in Mice.
Topics: Animals; Antidotes; Calcinosis; Calcium Gluconate; Hyaluronoglucosaminidase; Male; Mice; Mice, Inbre | 2018 |
Topical sodium thiosulfate for calcinosis cutis associated with autoimmune connective tissue diseases: the Mayo Clinic experience, 2012-2017.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Juvenile; Arthriti | 2019 |
Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate.
Topics: Administration, Topical; Adolescent; Biopsy, Needle; Calcinosis; Chronic Disease; Dermatomyositis; H | 2019 |
Reversing extraosseous calcifications. A case of breast uremic calcific arteriolopathy.
Topics: Arterioles; Breast Diseases; Calcinosis; Ergocalciferols; Female; Humans; Kidney Failure, Chronic; M | 2019 |
Calcium-solubilizing sodium thiosulfate failed to improve pulmonary alveolar microlithiasis: Evaluation of calcium content with CT scan.
Topics: Adult; Calcinosis; Calcium; Chelating Agents; Disease Progression; Female; Genetic Diseases, Inborn; | 2019 |
Treatment of a hemodialysis patient with pulmonary calcification-associated progressive respiratory failure with sodium thiosulfate.
Topics: Calcinosis; Chelating Agents; Humans; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle | 2013 |
Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease.
Topics: Adult; Calcinosis; Calcium; Chelating Agents; Dermatomyositis; Female; Humans; Injections, Intraderm | 2013 |
Sodium thiosulphate treatment of uraemic tumoral calcinosis.
Topics: Aged; Calcinosis; Comorbidity; Female; Humans; Hypertension; Incidence; Kidney Diseases; Kidney Fail | 2014 |
Treatment of Skin Calcifications with Intra-lesional Injection of Sodium Thiosulphate: A Case Series.
Topics: Aged; Calcinosis; Dermatologic Agents; Female; Humans; Injections, Intradermal; Injections, Intrales | 2016 |
Tumoural calcinosis in a young woman.
Topics: Calcinosis; Chelating Agents; Female; Hand Joints; Humans; Joint Diseases; Kidney Failure, Chronic; | 2016 |
Topical Sodium Thiosulfate: A Treatment for Calcifications in Hyperphosphatemic Familial Tumoral Calcinosis?
Topics: Administration, Topical; Adult; Calcinosis; Child; Female; Humans; Hyperostosis, Cortical, Congenita | 2016 |
Intravenous sodium thiosulfate for treating tumoral calcinosis associated with systemic disorders: Report of four cases.
Topics: Administration, Intravenous; Calcinosis; Chelating Agents; Humans; Thiosulfates | 2017 |
Bone scan findings in metastatic calcification from calciphylaxis.
Topics: Bone and Bones; Calcinosis; Calciphylaxis; Female; Humans; Ischemia; Kidney Failure, Chronic; Middle | 2008 |
Sodium thiosulfate prevents vascular calcifications in uremic rats.
Topics: Animals; Aortic Diseases; Bone and Bones; Calcinosis; Calcium; Kidney Diseases; Rats; Renal Circulat | 2008 |
Topical sodium thiosulfate therapy for leg ulcers with dystrophic calcification.
Topics: Administration, Topical; Adult; Calcinosis; Female; Humans; Immunosuppressive Agents; Leg Ulcer; Lup | 2008 |
Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient.
Topics: Adolescent; Antioxidants; Arterial Occlusive Diseases; Calcinosis; Combined Modality Therapy; Granul | 2010 |
Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients.
Topics: Aged; Bone Density; Calcinosis; Chelating Agents; Coronary Artery Disease; Disease Progression; Fema | 2010 |
The effect of topical sodium thiosulfate in experimentally induced myringosclerosis.
Topics: Administration, Topical; Animals; Calcinosis; Rats; Rats, Wistar; Thiosulfates; Tympanic Membrane | 2010 |
A novel treatment for ulcerative calcinosis cutis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Calcinosis; Female; Humans; Male; Skin Diseases; | 2011 |
A novel treatment for ulcerative calcinosis cutis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Calcinosis; Female; Humans; Male; Skin Diseases; | 2011 |
A novel treatment for ulcerative calcinosis cutis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Calcinosis; Female; Humans; Male; Skin Diseases; | 2011 |
A novel treatment for ulcerative calcinosis cutis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Calcinosis; Female; Humans; Male; Skin Diseases; | 2011 |
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.
Topics: Abatacept; Adolescent; Anti-Inflammatory Agents; Antioxidants; Calcinosis; Chelating Agents; Dermato | 2012 |
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.
Topics: Abatacept; Adolescent; Anti-Inflammatory Agents; Antioxidants; Calcinosis; Chelating Agents; Dermato | 2012 |
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.
Topics: Abatacept; Adolescent; Anti-Inflammatory Agents; Antioxidants; Calcinosis; Chelating Agents; Dermato | 2012 |
Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis.
Topics: Abatacept; Adolescent; Anti-Inflammatory Agents; Antioxidants; Calcinosis; Chelating Agents; Dermato | 2012 |
Dramatic diminution of a large calcification treated with topical sodium thiosulfate.
Topics: Administration, Topical; Antioxidants; Calcinosis; Child; Humans; Hyperostosis, Cortical, Congenital | 2012 |
Successful management of critical limb ischemia with intravenous sodium thiosulfate in a chronic hemodialysis patient.
Topics: Calcinosis; Calciphylaxis; Fingers; Humans; Infusions, Intravenous; Ischemia; Male; Middle Aged; Ren | 2006 |
Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism.
Topics: Antioxidants; Calcinosis; Chelating Agents; Female; Humans; Hyperparathyroidism; Joint Diseases; Kid | 1996 |
Sodium thiosulfate treatment of tumoral calcinosis in patients with end-stage renal disease.
Topics: Calcinosis; Female; Humans; Kidney Failure, Chronic; Male; Renal Dialysis; Thiosulfates | 1990 |